StockSelector.com
  Research, Select, & Monitor Monday, October 14, 2019 2:26:44 PM ET  
Trade Ideas The Market Industries Stocks Portfolio

 
Ticker Lookup
Amedisys, Inc.$130.05$.02.02%

  Quote | Ranking | Chart | Valuations | Sentiment | Industry | News | Earnings | Analysts | More...

Your Target?

 Amedisys Reports Fourth Quarter and Year End 2016 Financial Results
   Tuesday, February 28, 2017 6:44:00 PM ET

Amedisys, Inc. (AMED ) today reported its financial results for the three month period and year ended December 31, 2016.

<span data-mce-style="text-decoration: underline;" style="text-decoration: underline;">Three Month Periods Ended December 31, 2016 and 2015</span>

-- Net service revenue increased $27.9 million to $366.3 million compared to $338.4 million in 2015.

-- Net income attributable to Amedisys, Inc. of $8.9 million compared to $12.9 million in 2015.

-- Net income attributable to Amedisys, Inc. per diluted share of $0.26 per diluted share compared to $0.38 in 2015.

<span data-mce-style="text-decoration: underline;" style="text-decoration: underline;">Adjusted Quarterly Results*</span>

-- Adjusted net service revenue increased $27.8 million to $365.1 million compared to $337.3 million in 2015.

-- Adjusted EBITDA of $30.5 million compared to $27.6 million in 2015.

-- Adjusted net income attributable to Amedisys, Inc. of $15.0 million compared to $13.4 million in 2015.

-- Adjusted net income attributable to Amedisys, Inc. per diluted share of $0.44 compared to $0.40 in 2015.

<span data-mce-style="text-decoration: underline;" style="text-decoration: underline;">Years Ended December 31, 2016 and 2015 </span>

-- Net service revenue increased $156.9 million to $1,437.4 million compared to $1,280.5 million in 2015.

-- Net income attributable to Amedisys, Inc. of $37.3 million compared to $3.0 million net loss in 2015.

-- Net income attributable to Amedisys, Inc. per diluted share of $1.10 compared to $0.09 net loss per diluted share in 2015.

<span data-mce-style="text-decoration: underline;" style="text-decoration: underline;">Adjusted Year End Results* </span>

-- Adjusted net service revenue increased $157.8 million to $1,437.3 million compared to $1,279.5 million in 2015.

-- Adjusted EBITDA of $109.9 million compared to $112.0 million in 2015.

-- Adjusted net income attributable to Amedisys, Inc. of $52.2 million compared to $48.9 million in 2015.

-- Adjusted net income attributable to Amedisys, Inc. per diluted share of $1.55 compared to $1.48 in 2015.

* See Reconciliation of Non-GAAP Financial Measures to GAAP Measures in the table below.

Paul B. Kusserow, President and Chief Executive Officer stated, "I am extremely pleased with the results that our team delivered during 2016 and the fourth quarter, ahead of consensus estimates on EBITDA and earnings per share. Having completed our Homecare Homebase software implementation and rounding out our management team, we are already delivering a portion of the efficiencies that we promised to our stakeholders in early 2016. While the last few years have introduced quite a bit of change to the organization, our team has performed well across the board. Entering 2017, our primary goal for improvement is to return to consistent mid-single digit organic growth in home health. As a result of our efforts in the last few years, we have a solid and stable platform to build on, including a strong balance sheet that allows us to be opportunistic as we look to consolidate a fragmented industry."

We urge caution in considering the current trends disclosed in this press release. The home health and hospice industry is highly competitive and subject to intensive regulations, and trends are subject to numerous factors, risks, and uncertainties, some of which are referenced in the cautionary language below and others that are described more fully in our reports filed with the Securities and Exchange Commission ("SEC") including our Annual Report on Form 10-K for the fiscal year ended December 31, 2016, and subsequent Quarterly Reports on Form 10-Q, and current reports on Form 8-K which can be found on the SEC’s internet website, http://www.sec.gov, and our internet website, http://www.amedisys.com . We disclaim any obligations to update disclosed information on trends.

Earnings Call and Webcast Information

Amedisys will host a conference call on Wednesday, March 1, 2017, at 11:00 ET to discuss its fourth quarter and year end results. To participate on the conference call, please call a few minutes before 11:00 a.m. ET to either (877) 524-8416 (Toll-Free) or (412) 902-1028 (Toll). A replay of the conference call will be available through April 1, 2017 by dialing (877) 660-6853 (Toll-Free) or (201) 612-7415 (Toll) and entering conference ID #13654607.

A live webcast of the call will be accessible through our website on our Investor Relations section at the following web address: http://investors.amedisys.com .

Non-GAAP Financial Measures

This press release includes reconciliations of the most comparable financial measures calculated and presented in accordance with accounting principles generally accepted in the U.S. ("GAAP") to non-GAAP financial measures. The non-GAAP financial measures as defined under SEC rules are as follows: (1) Adjusted EBITDA, defined as net income (loss) attributable to Amedisys, Inc. before provision for income taxes, net interest expense and depreciation and amortization, excluding certain items; (2) adjusted net service revenue, defined as net service revenue excluding certain items; (3) adjusted net income attributable to Amedisys, Inc., defined as net income (loss) attributable to Amedisys, Inc. excluding certain items; and (4) adjusted net income attributable to Amedisys, Inc. per diluted share, defined as net income (loss) attributable to Amedisys, Inc. common stockholders per diluted share excluding certain items. Management believes that these non-GAAP financial measures, when reviewed in conjunction with GAAP financial measures, are useful gauges of our current performance and are also included in internal management reporting. These non-GAAP financial measures should be considered in addition to, and not more meaningful than or as an alternative to the GAAP financial measures presented in this earnings release and the company’s financial statements. Non-GAAP measures as presented herein may not be comparable to similarly titled measures reported by other companies since not all companies calculate these non-GAAP measures consistently.

Additional information

Amedisys, Inc. (the "Company") is a leading healthcare at home Company delivering personalized home health, hospice and personal care. Amedisys is focused on delivering the care that is best for our patients, whether that is home-based personal care; recovery and rehabilitation after an operation or injury; care focused on empowering them to manage a chronic disease; or hospice care at the end of life. More than 2,200 hospitals and 61,900 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, TN, Amedisys is a publicly held company. With approximately 16,000 employees, in 420 care centers in 34 states, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 385,000 patients in need every year. For more information about the Company, please visit: www.amedisys.com.

We use our website as a channel of distribution for important company information. Important information, including press releases, financial presentations and financial information regarding our company, is routinely posted on and accessible on the Investor Relations subpage of our website, which is accessible by clicking on the tab labeled "Investors" on our website home page. Visitors to our website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations subpage of our website.

Forward-Looking Statements

When included in this press release, words like "believes," "belief," "expects," "plans," "anticipates," "intends," "projects," "estimates," "may," "might," "would," "should" and similar expressions are intended to identify forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to the following: changes in Medicare and other medical payment levels, our ability to open care centers, acquire additional care centers and integrate and operate these care centers effectively, changes in or our failure to comply with existing federal and state laws or regulations or the inability to comply with new government regulations on a timely basis, competition in the healthcare industry, our ability to integrate our personal care segment into our business efficiently, changes in the case mix of patients and payment methodologies, changes in estimates and judgments associated with critical accounting policies, our ability to maintain or establish new patient referral sources, our ability to attract and retain qualified personnel, changes in payments and covered services due to the economic downturn and deficit spending by federal and state governments, future cost containment initiatives undertaken by third-party payors, our access to financing our ability to meet debt service requirements and comply with covenants in debt agreements, business disruptions due to natural disasters or acts of terrorism, our ability to integrate, manage and keep our information systems secure, our ability to comply with requirements stipulated in our corporate integrity agreement and changes in law or developments with respect to any litigation relating to the Company, including various other matters, many of which are beyond our control.

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events. We expressly disclaim any obligation or undertaking and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law.

AMEDISYS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEET
(Amounts in thousands, except share data)
(Unaudited)
                                                                                                                                                        December 31, 2016  December 31, 2015
ASSETS
Current assets:
Cash and cash equivalents                                                                                                                               $     30,197       $     27,502
Patient accounts receivable, net of allowance for doubtful accounts of $17,716 and $16,526                                                                    166,056            125,010
Prepaid expenses                                                                                                                                              7,397              8,110
Other current assets                                                                                                                                          11,260             14,641
Total current assets                                                                                                                                          214,910            175,263
Property and equipment, net of accumulated depreciation of $138,650 and $141,793                                                                              36,999             42,695
Goodwill                                                                                                                                                      288,957            261,663
Intangible assets, net of accumulated amortization of $27,864 and $25,386                                                                                     46,755             44,047
Deferred income taxes                                                                                                                                         107,940            125,245
Other assets, net                                                                                                                                             38,468             32,802
Total assets                                                                                                                                            $     734,029      $     681,715
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable                                                                                                                                        $     30,358       $     25,682
Payroll and employee benefits                                                                                                                                 82,480             72,546
Accrued expenses                                                                                                                                              63,290             71,965
Current portion of long-term obligations                                                                                                                      5,220              5,000
Total current liabilities                                                                                                                                     181,348            175,193
Long-term obligations, less current portion                                                                                                                   87,809             91,630
Other long-term obligations                                                                                                                                   3,730              4,456
Total liabilities                                                                                                                                             272,887            271,279
Equity:
Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding                                                                    --                 --
Common stock, $0.001 par value, 60,000,000 shares authorized; 35,253,577 and 34,786,966 shares issued; and 33,597,215 and 33,607,282 shares outstanding       35                 35
Additional paid-in capital                                                                                                                                    537,472            504,290
Treasury stock at cost, 1,656,362 and 1,179,684 shares of common stock                                                                                        (46,774 )          (26,966 )
Accumulated other comprehensive income                                                                                                                        15                 15
Retained earnings                                                                                                                                             (30,545 )          (67,806 )
Total Amedisys, Inc. stockholders’ equity                                                                                                                     460,203            409,568
Noncontrolling interests                                                                                                                                      939                868
Total equity                                                                                                                                                  461,142            410,436
Total liabilities and equity                                                                                                                            $     734,029      $     681,715
AMEDISYS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
(Amounts in thousands, except per share data)
(Unaudited)
                                                                     For the Three Month Period        For the Year
                                                                     Ended December 31,                Ended December 31,
                                                                         2016             2015         2016             2015
Net service revenue                                                  $   366,296      $   338,367      $  1,437,454     $  1,280,541
Cost of service, excluding depreciation and amortization                 212,589          192,483         833,055          725,915
General and administrative expenses:
Salaries and benefits                                                    75,902           69,628          306,981          279,425
Non-cash compensation                                                    3,845            4,187           16,401           11,824
Other                                                                    45,097           46,452          180,048          161,186
Provision for doubtful accounts                                          5,855            4,683           19,519           14,053
Depreciation and amortization                                            5,016            4,238           19,678           20,036
Asset impairment charge                                                  4,432            --              4,432            77,268
Operating expenses                                                       352,736          321,671         1,380,114        1,289,707
Operating income (loss)                                                  13,560           16,696          57,340           (9,166    )
Other income (expense):
Interest income                                                          30               38              75               71
Interest expense                                                         (1,613  )        (1,005  )       (5,164    )      (10,783   )
Equity in earnings from equity method investments                        1,986            1,122           5,588            9,823
Miscellaneous, net                                                       621              5,785           3,727            9,747
Total other income                                                       1,024            5,940           4,226            8,858
Income (loss) before income taxes                                        14,584           22,636          61,566           (308      )
Income tax expense                                                       (5,612  )        (9,564  )       (23,935   )      (2,004    )
Net income (loss)                                                        8,972            13,072          37,631           (2,312    )
Net income attributable to noncontrolling interests                      (55     )        (161    )       (370      )      (709      )
Net income (loss) attributable to Amedisys, Inc.                     $   8,917        $   12,911       $  37,261        $  (3,021    )
Basic earnings per common share:
Net income (loss) attributable to Amedisys, Inc. common stockholders $   0.27         $   0.39         $  1.12          $  (0.09     )
Weighted average shares outstanding                                      33,365           33,202          33,198           33,018
Diluted earnings per common share:
Net income (loss) attributable to Amedisys, Inc. common stockholders $   0.26         $   0.38         $  1.10          $  (0.09     )
Weighted average shares outstanding                                      33,866           33,743          33,741           33,018
AMEDISYS, INC. AND SUBSIDIARIES
SELECT CONSOLIDATED FINANCIAL STATEMENT INFORMATION AND SEGMENT INFORMATION
(Amounts in thousands, except statistical information)
(Unaudited)
                                                     For the Three Month Period
                                                     Ended December 31,                                                        For the Year Ended December 31,
                                                                           2016                       2015                                           2016                       2015
Net cash provided by operating activities            $                     28,561                   $ 20,044                   $                     62,259                   $ 107,785
Net cash used in investing activities                                      (6,649                )    (47,562               )                        (52,049               )    (67,421               )
Net cash used in financing activities                                      (630                  )    (2,031                )                        (7,515                )    (20,894               )
Net increase (decrease) in cash and cash equivalents                       21,282                     (29,549               )                        2,695                      19,470
Cash and cash equivalents at beginning of period                           8,915                      57,051                                         27,502                     8,032
Cash and cash equivalents at end of period           $                     30,197                   $ 27,502                   $                     30,197                   $ 27,502
Days revenue outstanding, net (1)                                          40.2                       31.9                                           40.2                       31.9
(1)  Our calculation of days revenue outstanding, net at December 31, 2016 and 2015 is derived by dividing our ending patient accounts receivable (i.e., net of estimated revenue adjustments and allowance for doubtful accounts) by our average daily net patient revenue for the three month period ended December 31, 2016 and 2015, respectively.
Segment Information - Home Health
                                           For the Three Month Period Ended December 31,
                                                                         2016                                2015
Financial Information (in millions):
Medicare                                   $                             203.2                             $ 195.7
Non-Medicare                                                             65.1                                66.9
Net service revenue                                                      268.3                               262.6
Cost of service                                                          160.1                               153.2
Gross margin                                                             108.2                               109.4
Other operating expenses                                                 72.7                                76.6
Operating income                           $                             35.5                              $ 32.8
Key Statistical Data:
Medicare:
Same Store (1):
Revenue                                                                  (1                            %)    5                             %
Admissions                                                               2                             %     3                             %
Recertifications                                                         (2                            %)    3                             %
Total (2):
Admissions                                                               47,637                              44,253
Recertifications                                                         25,628                              25,376
Completed episodes                                                       71,855                              68,926
Visits                                                                   1,230,434                           1,216,983
Average revenue per completed episode (3)  $                             2,851                             $ 2,855
Visits per completed episode (4)                                         17.2                                17.7
Non-Medicare:
Same Store (1):
Revenue                                                                  (2                            %)    25                            %
Admissions                                                               (3                            %)    15                            %
Recertifications                                                         (1                            %)    16                            %
Total (2):
Admissions                                                               24,309                              25,201
Recertifications                                                         9,673                               9,798
Visits                                                                   501,215                             529,948
Total (2):
Visiting Clinician Cost per Visit          $                             83.46                             $ 79.24
Clinical Manager Cost per Visit            $                             9.01                              $ 8.47
Total Cost per Visit                       $                             92.47                             $ 87.71
Visits                                                                   1,731,649                           1,746,931
                                           For the Year Ended December 31,
                                                                         2016                                2015
Financial Information (in millions):
Medicare                                   $                             822.4                             $ 761.4
Non-Medicare                                                             263.1                               243.7
Net service revenue                                                      1,085.5                             1,005.1
Cost of service                                                          643.7                               584.2
Gross margin                                                             441.8                               420.9
Other operating expenses                                                 303.2                               280.6
Operating income                           $                             138.6                             $ 140.3
Key Statistical Data:
Medicare:
Same Store (1):
Revenue                                                                  2                             %     3                             %
Admissions                                                               3                             %     3                             %
Recertifications                                                         0                             %     (1                            %)
Total (2):
Admissions                                                               194,662                             178,226
Recertifications                                                         103,193                             99,762
Completed episodes                                                       289,862                             269,227
Visits                                                                   5,124,002                           4,797,734
Average revenue per completed episode (3)  $                             2,839                             $ 2,825
Visits per completed episode (4)                                         17.5                                17.5
Non-Medicare:
Same Store (1):
Revenue                                                                  8                             %     21                            %
Admissions                                                               2                             %     18                            %
Recertifications                                                         8                             %     14                            %
Total (2):
Admissions                                                               98,448                              96,934
Recertifications                                                         38,618                              35,870
Visits                                                                   2,050,975                           1,954,543
Total (2):
Visiting Clinician Cost per Visit          $                             81.18                             $ 78.23
Clinical Manager Cost per Visit            $                             8.53                              $ 8.29
Total Cost per Visit                       $                             89.71                             $ 86.52
Visits                                                                   7,174,977                           6,752,277
(1)  Same store information represents the percent increase (decrease) in our Medicare and Non-Medicare revenue, admissions and recertifications for the period as a percent of the Medicare and Non-Medicare revenue, admissions and recertifications of the prior period.
(2)  Total includes acquisitions.
(3)  Average Medicare revenue per completed episode is the average Medicare revenue earned for each Medicare completed episode of care.
AMEDISYS, INC. AND SUBSIDIARIES
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES TO GAAP MEASURES
(Amounts in thousands)
(Unaudited)
Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization ("Adjusted EBITDA"):
                                                                                                 For the Three Month Period
                                                                                                 Ended December 31,              For the Year Ended December 31,
                                                                                                         2016         2015               2016           2015
Net income (loss) attributable to Amedisys, Inc.                                                 $       8,917      $ 12,911     $       37,261       $ (3,021    )
Add:
Income tax expense                                                                                       5,612        9,564              23,935         2,004
Interest expense, net                                                                                    1,583        967                5,089          10,712
Depreciation and amortization                                                                            5,016        4,238              19,678         20,036
Certain items (1)                                                                                        9,999        (120    )          24,559         85,447
Interest component of certain items (1)                                                                  (625    )    --                 (625      )    (3,212    )
Adjusted EBITDA (2) (6)                                                                          $       30,502     $ 27,560     $       109,897      $ 111,966
Adjusted Net Service Revenue Reconciliation:
                                                                                                 For the Three Month Period
                                                                                                 Ended December 31,              For the Year Ended December 31,
                                                                                                         2016         2015               2016           2015
Net service revenue                                                                              $       366,296    $ 338,367    $       1,437,454    $ 1,280,541
Add:
Certain items (1)                                                                                        (1,149  )    (1,059  )          (201      )    (1,059    )
Adjusted net service revenue (3) (6)                                                             $       365,147    $ 337,308    $       1,437,253    $ 1,279,482
Adjusted Net Income Attributable to Amedisys, Inc. Reconciliation:
                                                                                                 For the Three Month Period
                                                                                                 Ended December 31,              For the Year Ended December 31,
                                                                                                         2016         2015               2016           2015
Net income (loss) attributable to Amedisys, Inc.                                                 $       8,917      $ 12,911     $       37,261       $ (3,021    )
Add:
Certain items (1)                                                                                        6,114        543                14,923         51,898
Adjusted net income attributable to Amedisys, Inc. (4) (6)                                       $       15,031     $ 13,454     $       52,184       $ 48,877
Adjusted Net Income Attributable to Amedisys, Inc. per Diluted Share:
                                                                                                 For the Three Month Period
                                                                                                 Ended December 31,              For the Year Ended December 31,
                                                                                                         2016         2015               2016           2015
Net income (loss) attributable to Amedisys, Inc. common stockholders per diluted share           $       0.26       $ 0.38       $       1.10         $ (0.09     )
Add:
Certain items (1)                                                                                        0.18         0.02               0.44           1.57
Adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share (5) (6) $       0.44       $ 0.40       $       1.55         $ 1.48
(1) The following details the certain items for the three month periods and years ended December 31, 2016 and 2015:
Certain Items:
                                                                   For the Three Month Period                                                   For the Year Ended
                                                                   Ended December 31, 2016                                                      December 31, 2016
                                                                   (Income) Expense                                                             (Income) Expense
Certain Items Impacting Net Service Revenue:
Reduction of cost report reserve                                   $                                                                  (1,149 )  $                                                                  (1,149 )
Third party audit reserve                                                                                                             --                                                                           948
Certain Items Impacting Operating Expenses:
HCHB implementation                                                                                                                   1,345                                                                        8,371
Acquisition costs                                                                                                                     876                                                                          3,384
Legal fees - non-routine                                                                                                              543                                                                          1,992
Frontier litigation                                                                                                                   2,479                                                                        2,979
Wage and Hour litigation                                                                                                              (119   )                                                                     282
Asset impairment                                                                                                                      4,432                                                                        4,432
Restructuring activity                                                                                                                1,976                                                                        7,645
Sales/use tax audit reserve                                                                                                           460                                                                          460
Disaster relief                                                                                                                       129                                                                          467
Certain Items Impacting Total Other Income (Expense):
Sales/use tax audit reserve                                                                                                           625                                                                          625
Legal settlements                                                                                                                     (280   )                                                                     (2,328 )
Miscellaneous, other (income) expense, net                                                                                            (1,318 )                                                                     (3,549 )
Total                                                              $                                                                  9,999     $                                                                  24,559
Net of tax                                                         $                                                                  6,114     $                                                                  14,923
Diluted EPS                                                        $                                                                  0.18      $                                                                  0.44
                                                                   For the Three Month Period                                                   For the Year Ended
                                                                   Ended December 31, 2015                                                      December 31, 2015
                                                                   (Income) Expense                                                             (Income) Expense
Certain Items Impacting Net Service Revenue:
Reduction of cost report reserve                                   $                                                                  (1,059 )  $                                                                  (1,059 )
Certain Items Impacting Operating Expenses:
HCHB implementation                                                                                                                   2,383                                                                        4,431
Acquisition costs                                                                                                                     1,046                                                                        1,046
Legal fees - non-routine                                                                                                              459                                                                          745
OIG Self-Disclosure                                                                                                                   4,674                                                                        4,674
Inventory and Data Security Reporting                                                                                                 --                                                                           2,121
Wage and Hour litigation                                                                                                              (2,309 )                                                                     5,691
Asset impairment                                                                                                                      --                                                                           77,268
Restructuring activity                                                                                                                --                                                                           2,735
Certain Items Impacting Total Other Income (Expense):
Debt refinance costs                                                                                                                  --                                                                           3,212
Legal settlements                                                                                                                     (5,314 )                                                                     (7,453 )
Miscellaneous, other (income) expense, net                                                                                            --                                                                           (7,964 )
Total                                                              $                                                                  (120   )  $                                                                  85,447
Net of tax                                                         $                                                                  543       $                                                                  51,898
Diluted EPS                                                        $                                                                  0.02      $                                                                  1.57
(2)  Adjusted EBITDA is defined as net income (loss) attributable to Amedisys, Inc. before provision for income taxes, net interest expense and depreciation and amortization, excluding certain items as described in footnote 1.
(3)  Adjusted net service revenue is defined as net service revenue calculated in accordance with GAAP plus certain items as described in footnote 1.
(4)  Adjusted net income attributable to Amedisys, Inc. is defined as net income (loss) attributable to Amedisys, Inc. calculated in accordance with GAAP excluding certain items as described in footnote 1.
(5)  Adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share is defined as diluted income (loss) per share calculated in accordance with GAAP excluding the earnings per share effect of certain items as described in footnote 1.
(6)  Adjusted EBITDA, adjusted net service revenue, adjusted net income attributable to Amedisys, Inc. and adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share should not be considered as an alternative to, or more meaningful than, income before income taxes or other measure calculated in accordance with GAAP. These calculations may not be comparable to a similarly titled measure reported by other companies, since not all companies calculate these non-GAAP financial measures in the same manner.
Contact:

Investor Contact:
Amedisys, Inc.
David Castille
Managing Director, Treasury/Finance
(225) 299-3391
david.castille@amedisys.com

Media Contact:
Amedisys, Inc.
Kendra Kimmons
Managing Director, Marketing & Communications
(225) 299-3720
kendra.kimmons@amedisys.com

https://resource.globenewswire.com/Resource/Download/32390b23-b878-44c9-a504-f586109c0590?size=1

<img src="http://www.globenewswire.com/newsroom/ti?ndecode=MTUwIzY3MDUyMTM=" alt="" width="1" height="1"/>



Register |  Password |  Feedback |  Copyright |  Usage Agreement |  Privacy Policy |  Advertising |  About Us |  Contact Us |  FAQ 

Past performance is not indicative of future results

StockSelector.com, the StockSelector.com logo, and News Selects are trademarks of StockSelector.com.
Copyright © 1998 - 2019 StockSelector.com. All rights reserved.